|
Report No. : |
345832 |
|
Report Date : |
19.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
SEMOS PHARMACEUTICALS (PVT) LIMITED |
|
|
|
|
Registered Office : |
Plot # 11, Sector 12-A, North Karachi
Industrial Area, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1993 |
|
|
|
|
Com. Reg. No.: |
0029890 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical Products |
|
|
|
|
No. of Employees : |
118 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Pakistan |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SEMOS PHARMACEUTICALS (PVT) LIMITED
|
Registered
Address & Factory |
|
Plot # 11, Sector 12-A, North Karachi
Industrial Area, Karachi, Pakistan |
|
Tel # |
92 (21) 36985777, 36959167 |
|
Fax # |
92
(21) 36981277 |
|
Email |
|
a. |
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
b. |
Year Established |
1993 |
|
c. |
Registration No. |
0029890 |
Mowlai Mansion, Abba Somar Street,
Gari Khata, M. A. Jinnah Road,
Karachi, Pakistan
|
M. Akhtar & Company (Chartered Accountants) |
|
Subject Company was established as a Private Limited Company in 1993 |
|
Authorized Capital |
Rs. 50,000,000/- divided
into 500,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 46,890,000/-
divided into 468,900 shares of Rs. 100/- each |
|
Names |
Designation |
|
Mr. Abdullah Shamim Mrs. Rehana Aliya Mr. Tanzil-Ur-Rehman Mr. Muti-Ur-Rehman Mr. Fazal-Ur-Rehman |
Chief Executive Director Director Director Director |
|
Names |
No. of Shares |
|
Mr. Abdullah Shamim Mrs. Aliya Shamim Mr. Tanzil-Ur-Rehman Mr. Fazal-Ur-Rehman Mr. Muti-Ur-Rehman |
148,650 5,250 105,000 105,000 105,000 |
A. Subsidiary
None
B. Associated
Companies
- Do -
|
Manufacture &
marketing of Pharmaceutical Products by its brand names of BESTILO, CELECOXX,
CHLORPHEN IRAMINE TABS, LEXILIUM, MEFENAMIC ACID, MOVCOLM, PROMETHAZINE
ELIXIR, SEMOCOF, SEMORFEN, SEMOS-C, SEMOSIL, SEMOTOX, SEMOVET-N, SEMOZOL,
STOLAC, TRIMAGNA, VOLNAC |
118
|
The capacity and production of the Company’s
plant is indeterminable as it is multi-product and involves varying
processes of manufacture |
|
Subject normally import / purchases globally
from India,
Korea, China & European Countries.
It’s current global trade suppliers are Companies related to Pharmaceutical
Raw Materials |
|
Year |
In Pak Rupees |
|
2014 |
240,000,000/- (Estimated) |
|
Mainly exist at major cities of Pakistan |
|
(1) Allied Bank Limited, Pakistan. (2) United Bank
Limited, Pakistan. (3) Habib Metropolitan Bank Limited, Pakistan. (4) Habib Bank Limited, Pakistan. (5) Soneri Bank
Limited, Pakistan. (Total Mortgage obtained PKR: 183,957,000/-) |
Pakistan Pharmaceutical Manufacturers Association.(PPMA)
Karachi Chamber of Commerce & Industry.(KCCI)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 104.45 |
|
UK Pound |
1 |
Rs. 160.50 |
|
Euro |
1 |
Rs. 118.25 |
Subject Company was established in 1993 and
is engaged in manufacture & marketing of Pharmaceutical Products. Market
reputation is satisfactory. Trade relations are reported as fair. Subject can
be considered for normal business dealings at usual trade terms &
conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.64.97 |
|
|
1 |
Rs.100.55 |
|
Euro |
1 |
Rs.73.99 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.